Published Studies Related to Pneumovax (Pneumococcal Vaccine Polyvalent)
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster
randomised trial. 
invasive pneumococcal disease... INTERPRETATION: This nationwide trial showed high PHiD-CV10 effectiveness against
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. [2011.09]
CONCLUSIONS: : PHiD-CV and DTPa-IPV-Hib were immunogenic and well tolerated when coadministered as a 3-dose primary vaccination course.
Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. [2011.08]
BACKGROUND: We evaluated catch-up vaccination schedules with 10-valent pneumococcal nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)... CONCLUSIONS: A catch-up PHiD-CV schedule of 2 doses and booster for children 7 to 11 months of age was acceptable. For children 12 to 23 months of age, 2 doses seem to provide adequate priming although a booster dose might confer further benefit. Responses following 1 dose in children 2 to 5 years of age suggest that 2 doses may be preferable.
Pneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance. [2011.07.26]
Concerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption of neonatal vaccination. The aim of this study was to demonstrate the immunological feasibility of neonatal pneumococcal conjugate vaccination (PCV) which could potentially protect high-risk infants in resource poor countries against severe pneumococcal disease and mortality in the early critical period of life...
Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 x, 2 x, or 4 x) in healthy subjects aged 70 years or older. [2011.07.12]
Healthy adults aged >/= 70 years (N=443) with no history of pneumococcal vaccination received 7- or 9-valent pneumococcal conjugate vaccine (PCV7 or PCV9) at 1 x (PCV7 only), 2 x (PCV7+PCV9), or 4 x (2 x PCV7+2 x PCV9) dosage in a randomised, open-label study evaluating pneumococcal protein conjugate vaccine (PnC)...
Clinical Trials Related to Pneumovax (Pneumococcal Vaccine Polyvalent)
Study Evaluating Antibody Response of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children Previously Given PnC [Recruiting]
This is an open-label study (a study in which the doctors and participants know which drug
or vaccine is being administered) in children who previously received a 4-dose series of a
pneumococcal conjugate vaccine (PnC) during infancy in Study 6096A1-008-EU (NCT00366678).
In this study, participants will receive an additional dose of 13-valent pneumococcal
conjugate vaccine. The purpose of this study is to evaluate persistence, if any, of the
antibody response by measuring any remaining pneumococcal antibodies since the previous
study. This study will also evaluate the safety and immunogenicity of 13-valent
pneumococcal conjugate vaccine when administered at least 24 months after the last dose of
pneumococcal conjugate vaccine.
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria [Recruiting]
A vaccine called Prevenar is already approved for use in China for vaccination of children
younger than 6 years old against infections caused by Streptococcus pneumoniae.
This study is to measure the amount of antibodies (antibodies help people fight off
diseases) Chinese children aged between 121 days and 6 years (72 months) produce when given
Prevenar. The study will also provide more data on how safe and well tolerated Prevenar is
in Chinese children.
Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients [Not yet recruiting]
Ataxia-telangiectasia (AT) is a rare genetic disorder characterized by gait disorders,
neuromotor dysfunction, eye abnormalities and immune deficiency. AT patients are vulnerable
to cancer and infection and usually die during their 2nd or 3rd decade due to these
complications. The main cause of death is respiratory infections because these patients are
known to have severe type of immunodeficiency. Consequently, pneumonia is the most common
infection seen in AT patients, and is usually caused by S. pneumoniae. Therefore, a routine
schedule of pneumococcal vaccine is highly recommended in AT cases where immunoglobulin
replacement therapy was not already initiated.
Until recently, AT patients were immunized with the pneumococcal polysaccharide vaccine
(PPV23, Pneumovax® Aventis Pasteur MSD). However, data have shown that they do not respond
well to these vaccines. Recently, the Israeli Ministry of Health has approved the
pneumococcal 7-valent conjugate vaccine (PCV7, Prevenar®, Wyeth Lederle) for AT patients of
all ages. This conjugate vaccine is known to stimulate the immune system through a different
mechanism and the response is expected to be higher. The approved Israeli schedule for
immunization of AT patients includes children older than 2 years that are entitled to
receive 2 doses of PCV7 (8 weeks apart) boosted by PPV23, eight weeks after the second dose
of PCV7. Assessment of the antibody response of such pneumococcal vaccination protocol in AT
patients has never been performed.
The "Safra" Children's Hospital is the national multi-disciplinary center caring for AT
patients. Approximately 50 patients from all over the country (including Jewish, Druze,
Bedouin and other Muslim patients - 3 of whom are Palestinians) are followed in the clinic
on a monthly basis.
Approximately 20 AT patients are not receiving IVIG replacement therapy, therefore are
entitled to receive pneumococcal vaccination as stated above (mean age 10. 6, 3 - 23 years, 3
less than 5 years)
The aim of this study is to evaluate the responsiveness, determined by specific antibody
production, of AT patients receiving this new vaccine protocol.
Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients [Recruiting]
Severe Pneumococcal disease, such as bacteremia, meningitis and pneumonia, cause significant
morbidity and mortality in both otherwise healthy adult population and in the
immunocompromised patients. The incidence rate of invasive pneumococcal disease is
considerably higher among organ transplant patients than in healthy individuals. Routine
immunization with Pneumococcal vaccine is recommended pretransplant and once 3-5 years after
the transplantation. The efficacy and immunogenicity of Pneumococcal polysaccharide
vaccine(Pneumovax®) is suboptimal in this patient group. The conjugate Pneumococcal vaccine
has been shown to be more immunogenic and safe in some other subgroups of immunocompromised
patients. We intend to compare the immunogenicity of repeated dose 13-valent Pneumococcal
conjugate vaccine (Prevenar13®)to the existing recommended protocol of Pneumococcal
polysaccharide vaccine (Pneumovax®) in adult kidney and liver transplant patients.
Pneumococcal Conjugate Vaccine Followup [Recruiting]
Recently, controversy has emerged regarding the role of the 23vPPV in infants due to
potential immunological hypo-responsiveness (i. e. a poorer immune response to repeat
vaccination). Although previous experience of 23vPPV in children in PNG has demonstrated
protective efficacy against acute lower respiratory tract infection, the investigators feel
it is a matter of urgency to determine if 23vPPV administration provides elevated antibody
concentrations at 3 to 5 years of age, and to ensure the immunological safety of the 23vPPV
Following consent and eligibility assessment, a baseline blood sample and nose swab will be
taken, a 0. 1ml dose of 23vPPV will be administered and a follow up blood sample and nose
swab will be collected 28 days later. The investigators will also collect data on incidence
of ALRI in all study participants by medical record review.